Synairgen (SNG) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Sep 2024 07:00 AM
RNS
Appointment of New Chairman and Notice of AGM
05 Sep 2024 07:00 AM
RNS
Board Change
27 Jun 2024 07:00 AM
RNS
2023 Full Year Results
15 Nov 2023 07:00 AM
RNS
Grant of Options
11 Oct 2023 07:00 AM
RNS
Appointment of New Chief Financial Officer
03 Oct 2023 07:00 AM
RNS
Appointment of Chief Medical Officer
21 Sep 2023 07:00 AM
RNS
Interim Results
29 Jun 2023 06:02 PM
RNS
Result of AGM
29 Jun 2023 10:00 AM
RNS
Annual General Meeting Presentation
22 Jun 2023 07:00 AM
RNS
Grant of Options
23 May 2023 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
27 Apr 2023 07:00 AM
RNS
2022 Full Year Results
17 Apr 2023 07:00 AM
RNS
Notice of Full Year results
13 Mar 2023 04:40 PM
RNS
Second Price Monitoring Extn
13 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
03 Feb 2023 04:40 PM
RNS
Second Price Monitoring Extn
03 Feb 2023 04:35 PM
RNS
Price Monitoring Extension
17 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
13 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
13 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
23 Dec 2022 11:30 AM
RNS
SPRINTER Trial Results Published
14 Dec 2022 04:35 PM
RNS
Price Monitoring Extension
01 Dec 2022 07:00 AM
RNS
Board Changes
07 Nov 2022 04:40 PM
RNS
Second Price Monitoring Extn
07 Nov 2022 04:35 PM
RNS
Price Monitoring Extension
03 Nov 2022 04:40 PM
RNS
Second Price Monitoring Extn
03 Nov 2022 04:35 PM
RNS
Price Monitoring Extension
20 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
06 Oct 2022 01:35 PM
RNS
Holding(s) in Company
04 Oct 2022 07:02 AM
RNS
Data from the US NIH-led ACTIV-2 Phase 2 trial
29 Sep 2022 07:01 AM
RNS
Board Changes
29 Sep 2022 07:00 AM
RNS
Interim Results
20 Sep 2022 07:00 AM
RNS
SPRINTER Long COVID data presented at IDWeek
15 Sep 2022 07:00 AM
RNS
Notice of Interim Results
08 Sep 2022 04:40 PM
RNS
Second Price Monitoring Extn
08 Sep 2022 04:35 PM
RNS
Price Monitoring Extension
07 Sep 2022 07:00 AM
RNS
Positive Findings from SG015 Tri-al Analysis
05 Sep 2022 07:00 AM
RNS
Company Announce Collaboration on UNIVERSAL Trial
06 Jul 2022 07:00 AM
RNS
Grant of Options
30 Jun 2022 01:45 PM
RNS
Result of AGM
23 Jun 2022 04:40 PM
RNS
Second Price Monitoring Extn
23 Jun 2022 04:35 PM
RNS
Price Monitoring Extension
15 Jun 2022 02:30 PM
RNS
Holding(s) in Company
09 Jun 2022 03:00 PM
RNS
Exercise of Options and Total Voting Rights
06 Jun 2022 04:25 PM
RNS
Posting of Annual Report & Notice of AGM
25 May 2022 07:00 AM
RNS
Full Year Results
18 May 2022 04:36 PM
RNS
Price Monitoring Extension
16 May 2022 07:00 AM
RNS
Synairgen presents at ATS 2022
25 Apr 2022 07:00 AM
RNS
Presentation at ECCMID
19 Apr 2022 04:40 PM
RNS
Second Price Monitoring Extn

Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic.

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections.

Synairgen share price launched at 155p in 2004.

UK 100

Latest directors dealings